Locations:
SearchDr. Mikkael Sekeres in his latest New York Times column
Patients with cancer, and especially those receiving treatment, are approaching their physicians with questions about their risk of contracting COVID-19. Mikkael Sekeres, MD, MS, Director of Cleveland Clinic Cancer Center’s Leukemia Program, offers an expert’s perspective on the existing research in his latest New York Timescolumn. His answer to the question of whether cancer and chemotherapy increase the risk of death from COVID-19 provides a comprehensive look at existing research in patient-friendly language that can be a useful tool in communicating with your patients.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Read the column here.
Follow Dr. Sekeres on Twitter @MikkaelSekeres.
Advertisement
Advertisement
Global R&D efforts expanding first-line and relapse therapy options for patients
A case study on the value of access to novel therapies through clinical trials
Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients
Cleveland Clinic oncologists’ selected abstracts
On-demand stem cell mobilizer is an effective salvage strategy
Dispelling myths and sharing practical experiences
Research indicates strong rationale for expanding trial eligibility criteria
Retrospective study yields clues to understanding risk of secondary myeloid neoplasms